Compile Data Set for Download or QSAR
Report error Found 34 Enz. Inhib. hit(s) with all data for entry = 50014727
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146577(spirobenzoxazines analogues | CHEMBL102311)
Affinity DataIC50: 0.200nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146578(spirobenzoxazines analogues | CHEMBL103406)
Affinity DataIC50: 8nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146566(spirobenzoxazines analogues | CHEMBL440147)
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146565(spirobenzoxazines analogues | CHEMBL101157)
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146572(spirobenzoxazines analogues | CHEMBL100402)
Affinity DataIC50: 10nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146562(spirobenzoxazines analogues | CHEMBL100893)
Affinity DataIC50: 12nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146571(spirobenzoxazines analogues | CHEMBL101187)
Affinity DataIC50: 15nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146576(spirobenzoxazines analogues | CHEMBL316958)
Affinity DataIC50: 16nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146568(spirobenzoxazines analogues | CHEMBL101935)
Affinity DataIC50: 20nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146573(spirobenzoxazines analogues | CHEMBL101678)
Affinity DataIC50: 26nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146573(spirobenzoxazines analogues | CHEMBL101678)
Affinity DataIC50: 29nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146577(spirobenzoxazines analogues | CHEMBL102311)
Affinity DataIC50: 30nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146569(spirobenzoxazines analogues | CHEMBL430676)
Affinity DataIC50: 41nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146570(spirobenzoxazines analogues | CHEMBL100447)
Affinity DataIC50: 46nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146563(spirobenzoxazines analogues | CHEMBL316849)
Affinity DataIC50: 50nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146578(spirobenzoxazines analogues | CHEMBL103406)
Affinity DataIC50: 67nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146566(spirobenzoxazines analogues | CHEMBL440147)
Affinity DataIC50: 70nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146567(spirobenzoxazines analogues | CHEMBL320462)
Affinity DataIC50: 74nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146575(spirobenzoxazines analogues | CHEMBL317919)
Affinity DataIC50: 140nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146570(spirobenzoxazines analogues | CHEMBL100447)
Affinity DataIC50: 159nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146562(spirobenzoxazines analogues | CHEMBL100893)
Affinity DataIC50: 180nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146576(spirobenzoxazines analogues | CHEMBL316958)
Affinity DataIC50: 274nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146563(spirobenzoxazines analogues | CHEMBL316849)
Affinity DataIC50: 380nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146568(spirobenzoxazines analogues | CHEMBL101935)
Affinity DataIC50: 390nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146565(spirobenzoxazines analogues | CHEMBL101157)
Affinity DataIC50: 550nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146564(spirobenzoxazines analogues | CHEMBL100069)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146571(spirobenzoxazines analogues | CHEMBL101187)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146567(spirobenzoxazines analogues | CHEMBL320462)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146575(spirobenzoxazines analogues | CHEMBL317919)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146574(spirobenzoxazines analogues | CHEMBL103196)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin V1a receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146569(spirobenzoxazines analogues | CHEMBL430676)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146574(spirobenzoxazines analogues | CHEMBL103196)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146564(spirobenzoxazines analogues | CHEMBL100069)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50146572(spirobenzoxazines analogues | CHEMBL100402)
Affinity DataIC50: 1.00E+3nMAssay Description:In vitro inhibitory concentration against [3H]AVP binding to cloned human vasopressin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed